Skip to main content

Advertisement

Table 2 Treatment characteristics by second-line treatment group

From: Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer

  Chemotherapy only N = 38 Cetuximab N = 38 Bevacizumab N = 106 Total N = 182
Regimen used in 1st line therapy, n (%)     
Oxaliplatin based 5 (13%) 4 (11%) 54 (51%) 63 (35%)
Irinotecan based 21 (55%) 28 (74%) 40 (38%) 89 (49%)
Neither Oxaliplatin nor Irinotecan based 12 (32%) 6 (16%) 12 (11%) 30 (16%)
Regimen used in 2nd line therapy, n (%)     
5-FU 0 (0.0%) 0 (0.0%) 1 (0.9%) 1 (0.5%)
5-FU / AMG 706 / Irinotecan / Leucovorin 1 (2.6%) 0 (0.0%) 0 (0.0%) 1 (0.5%)
5-FU / Gamma Interferon / Irinotecan / Leucovorin 0 (0.0%) 0 (0.0%) 1 (0.9%) 1 (0.5%)
5-FU / Gamma Interferon / Leucovorin 2 (5.3%) 0 (0.0%) 0 (0.0%) 2 (1.1%)
5-FU / Interferon / Leucovorin 2 (5.3%) 0 (0.0%) 0 (0.0%) 2 (1.1%)
5-FU / Irinotecan / Leucovorin 6 (15.8%) 13 (34.2%) 29 (27.4%) 48 (26.4%)
5-FU / Irinotecan / Leucovorin / Oxaliplatin 0 (0.0%) 0 (0.0%) 5 (4.7%) 5 (2.7%)
5-FU / Irinotecan / Leucovorin / Oxaliplatin / Capecitabine 0 (0.0%) 0 (0.0%) 2 (1.9%) 2 (1.1%)
5-FU / Irinotecan / Leucovorin / Capecitabine 2 (5.3%) 0 (0.0%) 4 (3.8%) 6 (3.3%)
5-FU / Leucovorin 2 (5.3%) 1 (2.6%) 3 (2.8%) 6 (3.3%)
5-FU / Leucovorin / Oxaliplatin 3 (7.9%) 3 (7.9%) 38 (35.8%) 44 (24.2%)
5-FU / Leucovorin / Oxaliplatin / Capecitabine 0 (0.0%) 0 (0.0%) 1 (0.9%) 1 (0.5%)
Bevacizumab Only 0 (0.0%) 0 (0.0%) 2 (1.9%) 2 (1.1%)
Cetuximab Only 0 (0.0%) 4 (10.5%) 0 (0.0%) 4 (2.2%)
Floxuridine / Irinotecan 1 (2.6%) 0 (0.0%) 0 (0.0%) 1 (0.5%)
Irinotecan 11 (28.9%) 13 (34.2%) 3 (2.8%) 27 (14.8%)
Irinotecan / Oxaliplatin / Capecitabine 0 (0.0%) 0 (0.0%) 1 (0.9%) 1 (0.5%)
Irinotecan / Capecitabine 0 (0.0%) 2 (5.3%) 3 (2.8%) 5 (2.7%)
Oxaliplatin / Capecitabine 2 (5.3%) 1 (2.6%) 7 (6.6%) 10 (5.5%)
Capecitabine 6 (15.8%) 1 (2.6%) 6 (5.7%) 13 (7.1%)